The effect of beclomethasone dipropionate in ultrafine particles on bronchial hyper‐reactivity in young children
Aim: Bronchial hyper‐reactivity (BHR) provides a tool for asthma diagnosis, assessment of severity and response to treatment. The effect of beclomethasone dipropionate in ultrafine particles (BDP‐HFA) on BHR as measured by the adenosine challenge test in young children has not yet been determined. Our aim was to determine the effect of BDP‐HFA (100 μg twice daily) on BHR as evaluated by a reduction of 20% from baseline FEV1 (PC20‐FEV1) values in young asthmatic children.
Methods: Twenty‐one young children (13 males), mean age 4.95 ± 1.05 years, with partially controlled or controlled asthma completed a double‐blind randomized, placebo‐controlled, cross‐over study. Each child received 4 weeks of treatment with either 100 μg BDP‐HFA twice daily or placebo, and after a 2‐week washout period the other way around. Primary outcomes were PC20‐FEV1 concentration, and the stage number at which FEV1 values dropped by 20%.
Results: Following 4 weeks of treatment, median PC20‐FEV1 was 81.28 mg/mL while on BDP‐HFA, compared with 9.64 mg/mL on placebo (p < 0.001). The median increase in stages required to achieve PC20 on BDP‐HFA compared with placebo was three (95% CI 2.28–4.86).
Conclusion: Four weeks of treatment with BDP‐HFA resulted in significantly decreased BHR in young children.
Document Type: Research Article
Affiliations: 1: Pediatric Pulmonary Unit, Meyer Children’s Hospital, The Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel 2: Israel Poison Information Center, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
Publication date: 2012-05-01